Serum β-trace protein and risk of mortality in incident hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 9, 2012, Pages 1435-1445

  Shafi, Tariq ^a   Parekh, Rulan S ^b   Jaar, Bernard G ^b   Plantinga, Laura C ^b   Oberai, Pooja C ^b   Eckfeldt, John H ^b   Levey, Andrew S ^b   Powe, Neil R ^b   Coresh, Josef ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA TRACE PROTEIN; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; URINE VOLUME;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; INCIDENCE; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; LIPOCALINS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; UP-REGULATION;

EID: 84866078365     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02240312     Document Type: Article

References (54)

1. US Renal Data System: USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
2. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
3. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010-2019, 2002
4. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, JohnsonDW, Kesselhut J, Li JJ, LuxtonG, Pilmore A, Tiller DJ, Harris DC, Pollock CA; IDEAL Study: A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363: 609-619, 2010
5. Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J AmSoc Nephrol 12: 2158-2162, 2001
6. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serum beta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 17: 546-555, 2006
7. Diaz-Buxo JA, Lowrie EG, LewNL, Zhang SM, Zhu X, Lazarus JM: Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 33: 523-534, 1999
8. Maiorca R, Brunori G, Zubani R, Cancarini GC, Manili L, Camerini C, Movilli E, Pola A, D'Avolio G, Gelatti U: Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 10: 2295-2305, 1995
9. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; NECOSAD Study Group: Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15: 1061-1070, 2004
10. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT; NECOSAD Study Group: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of theNetherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41: 1293-1302, 2003
11. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S; Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307-1320, 2002
12. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11: 556-564, 2000
13. White CA, Akbari A, Doucette S, FergussonD, Hussain N, Dinh L, Filler G, Lepage N, Knoll GA: Estimating GFR using serum beta trace protein: Accuracy and validation in kidney transplant and pediatric populations. Kidney Int 76: 784-791, 2009
14. Benlamri A, Nadarajah R, Yasin A, LepageN, Sharma AP, FillerG: Development of a beta-trace protein based formula for estimation of glomerular filtration rate. Pediatr Nephrol 25: 485-490, 2010
15. Spanaus KS, Kollerits B, Ritz E, Hersberger M, Kronenberg F, von Eckardstein A; Mild and Moderate Kidney Disease (MMKD) Study Group: Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem 56: 740-749, 2010
16. Gerhardt T, Pöge U, Stoffel-Wagner B, Klein B, Klehr HU, Sauerbruch T, Woitas RP: Serum levels of beta-trace protein and its association to diuresis in haemodialysis patients. Nephrol Dial Transplant 23: 309-314, 2008
17. Powe NR, Klag MJ, Sadler JH, Anderson GF, Bass EB, BriggsWA, Fink NE, Levey AS, Levin NW, Meyer KB, Rubin HR, Wu AW: Choices for healthy outcomes in caring for end stage renal disease. Semin Dial 9: 9-11, 1996
18. Sanders EL, Clark RJ, Katzmann JA: Cerebrospinal fluid leakage: Agarose gel electrophoresis detection of beta(2)-transferrin and nephelometric quantification of beta-trace protein. Clin Chem 50: 2401-2403, 2004
19. Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J: High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 16: 1794-1802, 2005
20. Miskulin DC, Meyer KB, Athienites NV, Martin AA, Terrin N, Marsh JV, Fink NE, Coresh J, Powe NR, Klag MJ, Levey AS: Comorbidity and other factors associated with modality selection in incident dialysis patients: The CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease. Am J Kidney Dis 39: 324-336, 2002
21. Athienites NV, Miskulin DC, Fernandez G, Bunnapradist S, Simon G, Landa M, Schmid CH, Greenfield S, Levey AS, Meyer KB: Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Semin Dial 13: 320-326, 2000
22. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451-459, 2004
23. Harrell FE Jr: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis, New York, Springer, 2001
24. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, Powe NR, Coresh J: Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 56: 348-358, 2010
25. Penne EL, van derWeerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, NubéMJ, Bots ML, Lévesque R, ter Wee PM, Blankestijn PJ; CONTRAST investigators: Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 6: 281-289, 2011
26. Marquez IO, Tambra S, Luo FY, Li Y, Plummer NS, Hostetter TH, Meyer TW: Contribution of residual function to removal of proteinbound solutes in hemodialysis. Clin J Am Soc Nephrol 6: 290-296, 2011
27. Peritoneal Dialysis Adequacy Work Group: Clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 48 [Suppl 1]: S98-S129, 2006
28. Ros S, Bajo A, del Peso G, Garcia de Miguel A, Santacruz S, Fernandez E, deGarcia R, Selgas R:CystatinC asmarker of residual renal function in patients on peritoneal dialysis: Relation with parameters of peritoneal function. J Nephrol 20: 468-473, 2007
29. Delaney MP, Stevens PE, Al Hasani M, Stowe HJ, Judge C, Lamb EJ: Relationship of serum cystatin C to peritoneal and renal clearance measures in peritoneal dialysis: A cross-sectional study. Am J Kidney Dis 51: 278-284, 2008
30. Kim SJ, Sohn YB, Park SW, Jin DK, Paik KH: Serum cystatin C for estimation of residual renal function in children on peritoneal dialysis. Pediatr Nephrol 26: 433-440, 2011
31. Filler G, Huang SH, Lindsay RM: Residual renal function assessment with cystatin C. Pediatr Nephrol 26: 333-335, 2011
32. Al-Malki N, Heidenheim PA, Filler G, Yasin A, Lindsay RM: Cystatin C levels in functionally anephric patients undergoing dialysis: The effect of differentmethods and intensities. Clin J Am Soc Nephrol 4: 1606-1610, 2009
33. Lindström V, Grubb A, Alquist Hegbrant M, Christensson A: Different elimination patterns of beta-trace protein, beta2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration. Scand J Clin Lab Invest 68: 685-691, 2008
34. Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, Jung K: Beta-trace protein in serum: A new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem 45: 567-568, 1999
35. Donadio C, Lucchesi A, Ardini M, Donadio E, Giordani R: Serum levels of beta-trace protein and glomerular filtration rate-preliminary results. J Pharm Biomed Anal 32: 1099-1104, 2003
36. Hoffmann A, Nimtz M, Conradt HS: Molecular characterization of beta-trace protein in human serum and urine: A potential diagnostic marker for renal diseases. Glycobiology 7: 499-506, 1997
37. Nagata N, Fujimori K, Okazaki I, Oda H, Eguchi N, Uehara Y, Urade Y: De novo synthesis, uptake and proteolytic processing of lipocalin-type prostaglandin D synthase, beta-trace, in the kidneys. FEBS J 276: 7146-7158, 2009
38. Shin MJ, Song SH, Kwak IS, Lee SB, Lee DW, Seong EY, Kim IY, RheeH, Lee N: Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis. Clin Exp Nephrol, in press
39. Tanaka T, Urade Y, Kimura H, Eguchi N, Nishikawa A, Hayaishi O: Lipocalin-type prostaglandin D synthase (beta-trace) is a newly recognized type of retinoid transporter. J Biol Chem 272: 15789-15795, 1997
40. Beuckmann CT, Aoyagi M, Okazaki I, Hiroike T, Toh H, Hayaishi O, Urade Y: Binding of biliverdin, bilirubin, and thyroid hormones to lipocalin-type prostaglandin D synthase. Biochemistry 38: 8006-8013, 1999
41. Zhou Y, ShawN, Li Y, Zhao Y, Zhang R, Liu ZJ: Structure-function analysis of human l-prostaglandin D synthase bound with fatty acid molecules. FASEB J 24: 4668-4677, 2010
42. Saleem S, Shah ZA, Urade Y, DoréS: Lipocalin-prostaglandin D synthase is a critical beneficial factor in transient and permanent focal cerebral ischemia. Neuroscience 160: 248-254, 2009
43. Hattori Y, Levi R: Effect of PGD2 on cardiac contractility: A negative inotropism secondary to coronary vasoconstriction conceals a primary positive inotropic action. J Pharmacol Exp Ther 237: 719-724, 1986
44. Schrö r K: Prostaglandin D2 (PGD2)-a potent coronary vasoconstrictor agent in the guinea pig isolated heart. Naunyn Schmiedebergs Arch Pharmacol 302: 61-62, 1978
45. Eguchi Y, Eguchi N, Oda H, Seiki K, Kijima Y, Matsu-ura Y, Urade Y, Hayaishi O: Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci U S A 94: 14689-14694, 1997
46. Miwa Y, Oda H, Shiina Y, Shikata K, Tsushima M, Nakano S, Maruyama T, Kyotani S, Eguchi N, Urade Y, Takahashi-Yanaga F, Morimoto S, Sasaguri T: Association of serum lipocalin-type prostaglandin D synthase levels with subclinical atherosclerosis in untreated asymptomatic subjects. HypertensRes 31: 1931-1939, 2008
47. Inoue T, EguchiY, Matsumoto T, KijimaY, KatoY, OzakiY, WasedaK, Oda H, Seiki K, Node K, Urade Y: Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. Atherosclerosis 201: 385-391, 2008
48. Miwa Y, Takiuchi S, Kamide K, Yoshii M, Horio T, Tanaka C, Banno M, Miyata T, Sasaguri T, Kawano Y: Identification of gene polymorphism in lipocalin-type prostaglandinDsynthase and its association with carotid atherosclerosis in Japanese hypertensive patients. Biochem Biophys Res Commun 322: 428-433, 2004
49. Cipollone F, Cicolini G, Bucci M: Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives. Pharmacol Ther 118: 161-180, 2008
50. Siew ED, Ware LB, Ikizler TA: Biologicalmarkers of acute kidney injury. J Am Soc Nephrol 22: 810-820, 2011
51. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand S-LT, O'Donnell CJ, Smith SC Jr, Wilson PWF; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council: Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation 119: 2408-2416, 2009
52. Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA, Coresh J: Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis 59: 653-662, 2012
53. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serumcreatinine values in themodification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006
54. Daugirdas JT: Second generation logarithmic estimates of singlepool variable volume Kt/V: An analysis of error. J AmSoc Nephrol 4: 1205-1213, 1993